Does the media prefer BBIO or ELVN?

In the previous week, BridgeBio Pharma had 4 more articles in the media than Enliven Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 9 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.73 beat BridgeBio Pharma's score of 0.39 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HALO or ELVN?

In the previous week, Halozyme Therapeutics had 4 more articles in the media than Enliven Therapeutics. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 9 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.73 beat Halozyme Therapeutics' score of 0.42 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ELVN or SMMT?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is ELVN or SMMT more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Summit Therapeutics N/A -168.94% -141.92%

Does the media favor ELVN or SMMT?

In the previous week, Summit Therapeutics had 2 more articles in the media than Enliven Therapeutics. MarketBeat recorded 11 mentions for Summit Therapeutics and 9 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.73 beat Summit Therapeutics' score of 0.44 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MDGL or ELVN?

In the previous week, Enliven Therapeutics had 6 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 9 mentions for Enliven Therapeutics and 3 mentions for Madrigal Pharmaceuticals. Enliven Therapeutics' average media sentiment score of 0.73 beat Madrigal Pharmaceuticals' score of 0.38 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BMRN or ELVN?

In the previous week, BioMarin Pharmaceutical had 5 more articles in the media than Enliven Therapeutics. MarketBeat recorded 14 mentions for BioMarin Pharmaceutical and 9 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.73 beat BioMarin Pharmaceutical's score of 0.46 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enliven Therapeutics (ELVN) Competitors

$41.36 -1.03 (-2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$41.37 +0.01 (+0.02%)

As of 07:52 PM Eastern

Compare

ELVN vs. BBIO, HALO, SMMT, MDGL, and BMRN

Should you buy Enliven Therapeutics stock or one of its competitors? Enliven Therapeutics's main competitors and comparable companies include BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), Summit Therapeutics (SMMT), Madrigal Pharmaceuticals (MDGL), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Enliven Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Enliven Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Enliven Therapeutics	N/A	-18.55%	-18.09%

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BridgeBio Pharma had 4 more articles in the media than Enliven Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 9 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.73 beat BridgeBio Pharma's score of 0.39 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma presently has a consensus price target of $102.61, indicating a potential upside of 53.24%. Enliven Therapeutics has a consensus price target of $74.44, indicating a potential upside of 75.62%. Given Enliven Therapeutics' higher probable upside, analysts clearly believe Enliven Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Enliven Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Enliven Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.07	-$724.93M	-$3.57	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Summary

BridgeBio Pharma beats Enliven Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

In the previous week, Halozyme Therapeutics had 4 more articles in the media than Enliven Therapeutics. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 9 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.73 beat Halozyme Therapeutics' score of 0.42 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics presently has a consensus price target of $91.20, indicating a potential downside of 16.88%. Enliven Therapeutics has a consensus price target of $74.44, indicating a potential upside of 75.62%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Halozyme Therapeutics has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.92	$316.89M	$3.35	32.75
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 24.86% compared to Enliven Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Enliven Therapeutics	N/A	-18.55%	-18.09%

Summary

Halozyme Therapeutics beats Enliven Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Summit Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Enliven Therapeutics presently has a consensus target price of $74.44, indicating a potential upside of 75.62%. Summit Therapeutics has a consensus target price of $28.61, indicating a potential upside of 65.27%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Enliven Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

In the previous week, Summit Therapeutics had 2 more articles in the media than Enliven Therapeutics. MarketBeat recorded 11 mentions for Summit Therapeutics and 9 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.73 beat Summit Therapeutics' score of 0.44 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics' return on equity of -18.55% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Summit Therapeutics	N/A	-168.94%	-141.92%

Enliven Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, suggesting that its share price is 251% less volatile than the broader market.

Summary

Enliven Therapeutics beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Enliven Therapeutics compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

In the previous week, Enliven Therapeutics had 6 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 9 mentions for Enliven Therapeutics and 3 mentions for Madrigal Pharmaceuticals. Enliven Therapeutics' average media sentiment score of 0.73 beat Madrigal Pharmaceuticals' score of 0.38 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Enliven Therapeutics' return on equity of -18.55% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Enliven Therapeutics	N/A	-18.55%	-18.09%

Madrigal Pharmaceuticals presently has a consensus price target of $710.20, suggesting a potential upside of 43.06%. Enliven Therapeutics has a consensus price target of $74.44, suggesting a potential upside of 75.62%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enliven Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Enliven Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.97	-$288.28M	-$12.89	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Enliven Therapeutics beats Madrigal Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Enliven Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Enliven Therapeutics	N/A	-18.55%	-18.09%

BioMarin Pharmaceutical has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.38	$348.90M	$0.37	151.95
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

BioMarin Pharmaceutical has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BioMarin Pharmaceutical presently has a consensus target price of $89.17, indicating a potential upside of 58.62%. Enliven Therapeutics has a consensus target price of $74.44, indicating a potential upside of 75.62%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enliven Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.67
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, BioMarin Pharmaceutical had 5 more articles in the media than Enliven Therapeutics. MarketBeat recorded 14 mentions for BioMarin Pharmaceutical and 9 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.73 beat BioMarin Pharmaceutical's score of 0.46 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioMarin Pharmaceutical beats Enliven Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELVN vs. The Competition

Export

Metric	Enliven Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.11B	$3.84B	$7.17B	$13.44B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-24.77	13.73	274.55	26.10
Price / Sales	N/A	1,207.54	581.05	87.34
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	5.34	15.97	10.73	6.27
Net Income	-$103.69M	-$22.65M	$3.50B	$382.03M
7 Day Performance	-9.77%	-4.53%	-1.54%	-0.89%
1 Month Performance	-30.28%	-12.54%	-6.72%	-5.32%
1 Year Performance	105.67%	13.40%	5.74%	0.76%

Enliven Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELVN Enliven Therapeutics	2.9014 of 5 stars	$41.36 -2.4%	$74.44 +80.0%	+108.8%	$3.11B	N/A	N/A	67	News Coverage Insider Trade
BBIO BridgeBio Pharma	3.2306 of 5 stars	$65.97 -1.0%	$102.61 +55.5%	+22.6%	$13.02B	$502.08M	N/A	839	News Coverage Analyst Forecast
HALO Halozyme Therapeutics	3.0124 of 5 stars	$111.56 -1.2%	$91.20 -18.3%	+63.8%	$12.81B	$1.40B	33.30	423	Trending News Analyst Forecast
SMMT Summit Therapeutics	2.8132 of 5 stars	$16.39 +5.9%	$28.45 +73.6%	-21.9%	$12.35B	N/A	N/A	265	Analyst Forecast High Trading Volume
MDGL Madrigal Pharmaceuticals	2.8619 of 5 stars	$509.44 -1.5%	$710.20 +39.4%	+12.2%	$11.95B	$958.40M	N/A	915	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELVN) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enliven Therapeutics (ELVN) Competitors

ELVN vs. BBIO, HALO, SMMT, MDGL, and BMRN

How does Enliven Therapeutics compare to BridgeBio Pharma?

Summary

How does Enliven Therapeutics compare to Halozyme Therapeutics?

Summary

How does Enliven Therapeutics compare to Summit Therapeutics?

Summary

How does Enliven Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Enliven Therapeutics compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enliven Therapeutics (ELVN) Competitors

ELVN vs. BBIO, HALO, SMMT, MDGL, and BMRN

How does Enliven Therapeutics compare to BridgeBio Pharma?

Is BBIO or ELVN more profitable?

Do institutionals & insiders believe in BBIO or ELVN?

Does the media prefer BBIO or ELVN?

Do analysts prefer BBIO or ELVN?

Which has preferable valuation & earnings, BBIO or ELVN?

Which has more volatility & risk, BBIO or ELVN?

Summary

How does Enliven Therapeutics compare to Halozyme Therapeutics?

Does the media refer more to HALO or ELVN?

Do analysts recommend HALO or ELVN?

Which has stronger valuation and earnings, HALO or ELVN?

Which has more volatility & risk, HALO or ELVN?

Do insiders and institutionals have more ownership in HALO or ELVN?

Is HALO or ELVN more profitable?

Summary

How does Enliven Therapeutics compare to Summit Therapeutics?

Do insiders & institutionals believe in ELVN or SMMT?

Which has preferable valuation and earnings, ELVN or SMMT?

Do analysts recommend ELVN or SMMT?

Does the media favor ELVN or SMMT?

Is ELVN or SMMT more profitable?

Which has more volatility and risk, ELVN or SMMT?

Summary

How does Enliven Therapeutics compare to Madrigal Pharmaceuticals?

Does the media refer more to MDGL or ELVN?

Is MDGL or ELVN more profitable?

Do analysts recommend MDGL or ELVN?

Which has higher earnings & valuation, MDGL or ELVN?

Which has more risk and volatility, MDGL or ELVN?

Do insiders & institutionals hold more shares of MDGL or ELVN?

Summary

How does Enliven Therapeutics compare to BioMarin Pharmaceutical?

Is BMRN or ELVN more profitable?

Which has stronger earnings & valuation, BMRN or ELVN?

Which has more risk & volatility, BMRN or ELVN?

Do insiders and institutionals believe in BMRN or ELVN?

Do analysts prefer BMRN or ELVN?

Does the media refer more to BMRN or ELVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools